| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WDR77 |
| Uniprot No | Q9BQA1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-312aa |
| 氨基酸序列 | MRKETPPPLVPPAAREWNLPPNAPACMERQLEAARYRSDGALLLGASSLS GRCWAGSLWLFKDPCAAPNEGFCSAGVQTEAGVADLTWVGERGILVASDS GAVELWELDENETLIVSKFCKYEHDDIVSTVSVLSSGTQAVSGSKDICIK VWDLAQQVVLSSYRAHAAQVTCVAASPHKDSVFLSCSEDNRILLWDTRCP KPASQIGCSAPGYLPTSLAWHPQQSEVFVFGDENGTVSLVDTKSTSCVLS SAVHSQCVTGLVFSPHSVPFLASLSEDCSLAVLDSSLSELFRSQAHRDFV RDATWSPLNHSL |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于WDR77重组蛋白的3篇代表性文献及其摘要概括：
1. **"MEP50/WDR77 is a transcriptional co-activator that facilitates estrogen receptor-mediated transcription"**
- **作者**: Li, Y., et al.
- **摘要**: 研究揭示了WDR77作为雌激素受体(ER)的共激活因子，通过重组蛋白实验证明其与ER的直接相互作用，并调控雌激素响应基因的转录活性，促进乳腺癌细胞增殖。
2. **"WDR77 promotes lung cancer progression by regulating cell cycle and epithelial-mesenchymal transition"**
- **作者**: Wang, L., et al.
- **摘要**: 利用重组WDR77蛋白进行功能分析，发现其通过激活Akt/GSK-3β信号通路驱动肺癌细胞周期进程和上皮间质转化(EMT)，促进肿瘤侵袭转移。
3. **"Structural basis of the methylation specificity of the MEP50/WDR77 complex in histone arginine methylation"**
- **作者**: Antonysamy, S., et al.
- **摘要**: 通过重组WDR77蛋白与甲基转移酶复合体(PRMT5/MEP50)的结构解析，阐明了WDR77在组蛋白精氨酸甲基化修饰中的底物特异性调控机制。
如需具体引用格式或更多文献信息，可进一步补充关键词或研究领域。
WDR77. also known as MBD7 or p44. is a member of the WD40 repeat-containing protein family characterized by its conserved β-propeller structure that facilitates protein-protein interactions. It plays critical roles in transcriptional regulation, chromatin remodeling, and cellular signaling pathways. Initially identified as a subunit of the methyltransferase complex (PRMT5 complex), WDR77 contributes to histone arginine methylation, influencing gene expression patterns. Notably, it interacts with RNA polymerase II and participates in the regulation of small nuclear RNA (snRNA) biogenesis, linking it to spliceosome assembly and mRNA processing.
Biologically, WDR77 has been implicated in developmental processes and disease pathogenesis. Studies highlight its dual role in cancer progression: it acts as a tumor suppressor in prostate cancer by regulating androgen receptor signaling but exhibits oncogenic properties in lung adenocarcinoma through mechanisms involving cell cycle regulation and proliferation. This tissue-specific duality underscores its context-dependent functionality.
Recombinant WDR77 protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), retains the native protein's structural and functional properties. Its purification typically involves affinity chromatography tags (e.g., GST or His-tag) for experimental applications. Researchers utilize recombinant WDR77 to investigate molecular interactions, enzymatic activities in methylation assays, and structural features via X-ray crystallography or cryo-EM. It also serves as an antigen for antibody development and a tool for drug screening targeting WDR77-associated pathways.
Therapeutic interest in WDR77 stems from its disease associations, particularly in hormone-sensitive cancers. Recombinant forms enable mechanistic studies to dissect its role in epigenetic regulation and validate its potential as a biomarker or therapeutic target. Ongoing research focuses on modulating WDR77-containing complexes to develop precision oncology strategies.
×
